With an annual salary of 240,000 yuan, the core technical personnel of this in vitro diagnostic company left!

【Pharmaceutical Network Enterprise News】On September 29, the domestic hematology in vitro diagnostic company Sai Ke Xide issued an announcement that Zhang Lijun, a core technical person of the company, recently applied to the company to resign from the relevant position due to personal reasons, and has completed the relevant resignation procedures
.
After leaving, Zhang Lijun no longer holds any position in the
company.
It is reported that Zhang Lijun is the core technical personnel in the young team of Sekoshide Company, 33 years old, from May 2016 to enter the company as a reagent technician, and from May 2019 to now, as the company's reagent research and development department coagulation system research and development team director, mainly responsible for the study of lupus anticoagulant reagents based on coagulation method to study the activation pathway of coagulation
.
According to the 2021 annual report, Zhang Lijun's annual salary is 245,700 yuan
.
According to the announcement, Ms.
Zhang Lijun signed the "Confidentiality Agreement on Keeping Trade Secrets and Related to Intellectual Property Rights" with the company, and the patents applied for as a co-inventor during her tenure are all job results, and the ownership belongs to the company, does not involve rights disputes or potential disputes, and her departure will not affect the integrity
of the company's patent rights.
The work responsible for Ms.
Zhang Lijun has been handed over, and the company's production and operation, technology research and development and other work have been promoted
in an orderly manner.
Ms.
Zhang Lijun's departure will not have a substantial impact on
the company's operating ability, research and development strength, and core competitiveness.
As of the end of 2020 and the end of 2021, the number of R&D personnel in the company is 45 and 40, accounting for 15.
96% and 15.
04% of the total number of employees, respectively, and the number of R&D personnel remains stable
.
Before and after this change, the company's core technical personnel are left with 11
.
The announcement pointed out that the company attaches great importance to the construction of the R & D team, while continuing to increase investment in R & D, and constantly carry out the construction and improvement of the R & D system and R & D team, through a variety of ways for the company's R & D team to cultivate reserve new forces, the introduction of high-quality talents, continue to build a R & D talent echelon, to ensure the company's R & D innovation capabilities
.
According to the data, SecoSide is a developer of hematology in vitro diagnostic reagents and equipment, covering various mainstream in vitro diagnostic equipment and reagents such as hemagglutination, blood rheology, platelet aggregation, and erythrocyte sedimentation
.
At the same time, it has a three-level after-sales service network, and the service outlets are all over 30 provinces across
the country.
The 2021 annual report shows that the company achieved operating income of 240 million yuan during the reporting period, an increase of 7.
88% year-on-year; Net profit attributable to shareholders of listed companies was 97.
3688 million yuan, an increase of 40.
73% year-on-year; Basic earnings per share of RMB1.
19, and a cash dividend of RMB2.
5 (including tax)
is proposed to be paid to all shareholders for every 10 shares.
During the reporting period, the company actively promoted product and technology research and development, and continued to innovate
.
Focusing on the innovation and development of thrombosis and hemostasis in vitro diagnostic industry, the company continuously carries out product and technological innovation based on the existing core technology platform, actively accelerates the research and development process of new products, and strives to seize market opportunities; At the same time, according to clinical needs and technology development trends, we will continuously optimize and improve the existing product system, promote the research and development progress of products, and improve product performance to meet the diversified needs
of the market.
In 2021, the company invested a total of 15.
2056 million yuan in research and development expenses, accounting for 6.
34% of the operating income, and the research and development expenses increased by 0.
33 percentage points over
the same period last year.
During the reporting period, 3 newly acquired invention patents, 2 software copyrights, and 2 medical device industry standards that the company participated in were approved for publication
.
At present, the company has 17 research projects, and 3 new projects in 2021
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.